Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group

Dennis A Eichenauer; Annette Plütschow; Stefanie Kreissl; Martin Sökler; Johannes C Hellmuth; Julia Meissner; Stephan Mathas; Max S Topp; Karolin Behringer; Wolfram Klapper; Georg Kuhnert; Markus Dietlein; Carsten Kobe; Michael Fuchs; Volker Diehl; Andreas Engert; Peter Borchmann

doi:10.1016/s1470-2045(17)30696-4

Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group

The Lancet Oncology ◽

10.1016/s1470-2045(17)30696-4 ◽

2017 ◽

Vol 18 (12) ◽

pp. 1680-1687 ◽

Cited By ~ 36

Author(s):

Dennis A Eichenauer ◽

Annette Plütschow ◽

Stefanie Kreissl ◽

Martin Sökler ◽

Johannes C Hellmuth ◽

...

Keyword(s):

Randomised Trial ◽

Final Analysis ◽

Brentuximab Vedotin ◽

Hodgkin's Lymphoma ◽

Study Group ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

German Hodgkin Study Group ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732115130.793552724 ◽

2018 ◽

Author(s):

Boris Böll

Keyword(s):

Randomised Trial ◽

Final Analysis ◽

Brentuximab Vedotin ◽

Hodgkin's Lymphoma ◽

Study Group ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

German Hodgkin Study Group ◽

First Line Treatment

Download Full-text

Dose-Adjusted EPOCH Regimen as First-Line Treatment for Non-Hodgkin's Lymphoma with Hemophagocytic Lymphohistiocytosis: A Single-Arm, Open-Label, Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3304299 ◽

2018 ◽

Author(s):

Jin-Hua Liang ◽

Li Wang ◽

Hua-Yuan Zhu ◽

Jun Qian ◽

Hui Liao ◽

...

Keyword(s):

Hemophagocytic Lymphohistiocytosis ◽

Hodgkin's Lymphoma ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Non Hodgkin's Lymphoma ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

CLINICAL OUTCOMES OF RELAPSED HODGKIN LYMPHOMA PATIENTS AFTER CONTEMPORARY FIRST‐LINE TREATMENT: RESULTS FROM THE GERMAN HODGKIN STUDY GROUP

Hematological Oncology ◽

10.1002/hon.107_2880 ◽

2021 ◽

Vol 39 (S2) ◽

Author(s):

P. J. Bröckelmann ◽

H. Müller ◽

S. Gillessen ◽

X. Yang ◽

L. Koeppel ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Clinical Outcomes ◽

Study Group ◽

Line Treatment ◽

First Line ◽

Treatment Results ◽

German Hodgkin Study Group ◽

First Line Treatment

Download Full-text

Final analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.3540 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 3540-3540 ◽

Cited By ~ 2

Author(s):

N. Moosmann ◽

L. Fischer von Weikersthal ◽

U. Vehling-Kaiser ◽

M. Stauch ◽

H. F. Dietzfelbinger ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Randomized Trial ◽

Final Analysis ◽

Study Group ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text

Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour I'Etude des Cancers Ovariens

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70319-1 ◽

2007 ◽

Vol 2007 ◽

pp. 69-70

Author(s):

J.T. Thigpen

Keyword(s):

Ovarian Cancer ◽

Gynecologic Cancer ◽

Advanced Ovarian Cancer ◽

Study Group ◽

Line Treatment ◽

First Line ◽

Cancer Study ◽

Cancer Study Group ◽

Intergroup Trial ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717964930.793468200 ◽

2012 ◽

Author(s):

Yoshio Yamaoka ◽

Seiji Shiota

Keyword(s):

Helicobacter Pylori ◽

Triple Therapy ◽

Randomised Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727549021.793550895 ◽

2018 ◽

Author(s):

Sebastian Stintzing

Keyword(s):

Overall Survival ◽

Colorectal Carcinoma ◽

Final Analysis ◽

Line Treatment ◽

Metastatic Colorectal Carcinoma ◽

First Line ◽

First Line Treatment

Download Full-text

P5-5 Phase 2/3 study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer

Annals of Oncology ◽

10.1016/j.annonc.2021.05.684 ◽

2021 ◽

Vol 32 ◽

pp. S333

Author(s):

Do-Youn Oh ◽

Filippo de Braud ◽

John Bridgewater ◽

Junji Furuse ◽

Chih-Hung Hsu ◽

...

Keyword(s):

Biliary Tract ◽

Biliary Tract Cancer ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Tract Cancer ◽

First Line Treatment

Download Full-text

Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study

Cancer ◽

10.1002/cncr.29864 ◽

2016 ◽

Vol 122 (9) ◽

pp. 1434-1443 ◽

Cited By ~ 20

Author(s):

Didier Meulendijks ◽

Jan Willem B. de Groot ◽

Maartje Los ◽

James E. Boers ◽

Laurens V. Beerepoot ◽

...

Keyword(s):

Gastric Cancer ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Multicenter Phase ◽

Phase 2 Study ◽

First Line Treatment

Download Full-text

A Multi-Institutional Randomized Phase 2 Trial of the Oncolytic Virus Reolysin in the First Line Treatment Metastatic Adenocarcinoma of the Pancreas (Map)

Annals of Oncology ◽

10.1093/annonc/mdu438.19 ◽

2014 ◽

Vol 25 ◽

pp. v1 ◽

Cited By ~ 5

Author(s):

T. Bekaii-Saab ◽

A.M. Noonan ◽

G. Lesinski ◽

S. Mikhail ◽

K. Ciombor ◽

...

Keyword(s):

Oncolytic Virus ◽

Line Treatment ◽

Metastatic Adenocarcinoma ◽

Phase 2 ◽

First Line ◽

Phase 2 Trial ◽

Adenocarcinoma Of The Pancreas ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text